Back to Immuno-oncology: An Overview for Oncology Pharmacists
Immuno-oncology: An Overview for Oncology Pharmacists

Immuno-oncology: An Overview for Oncology Pharmacists

Faculty

 

Jennifer Swank, PharmD BCOP

Medical Oncology Clinical Pharmacist

Moffitt Cancer Center

Product Details

Module 1: Introduction and Overview to Immuno-Oncology

 

General introduction to the immune system and its interaction with cancer.  This module will cover the pharmacology and therapeutic use of immunotherapy and adoptive cell therapy including checkpoint inhibitors, TCR, and CAR-T cell therapy.  Discussion on PDL-1 testing and application to treatment with checkpoint inhibitors is also discussed

Learning Objectives

After completing this module learners should be able to . . .

·         Outline the mechanism of action of immunotherapy-related adverse effects (irAE)

·         Review the multidisciplinary NCCN and ASCO guidelines for the identification and management of irAE

·         Apply guideline driven management irAE management to patient care

·         Understand and apply patient education principles in daily practice

·         Outline the mechanism of active of cytokine release syndrome (CRS) and CAR-T cell related encephalopathy syndrome (CRES) from CAR-T therapy

·         Recommend strategies for CRS and CRES management from CAR-T therapy

 

Module 2: Management of Immunotherapy Related Adverse Effects (irAE)

Discuss the pathophysiology and management of irAE.  Comprehensive review and patient case centered learning model of the NCCN guidelines, ASCO guidelines, and ASBMT guidelines for the treatment of irAE from checkpoint inhibitor therapy and CRS and CRES management from CAR-T cell therapy.  Also provides guidelines for interaction and discussion with patients regarding these toxicities.

 

Learning Objectives

After completing this module learners should be able to . . .

       Outline the mechanism of action of immunotherapy-related adverse effects (irAE)

       Review the multidisciplinary NCCN and ASCO guidelines for the identification and management of irAE

       Apply guideline driven management irAE management to patient care

       Understand and apply patient education principles in daily practice

       Outline the mechanism of active of cytokine release syndrome (CRS) and CAR-T cell related encephalopathy syndrome (CRES) from CAR-T therapy

       Recommend strategies for CRS and CRES management from CAR-T therapy

 

Module 3: Immuno-Oncology Updates

Review of the FDA immunotherapy approvals since January of 2018.  Discuss potential new immunotherapy agents in the pipeline for FDA approval

Learning Objectives

After completing this module learners should be able to . . .

·         Outline the mechanism of action of immunotherapy-related adverse effects (irAE)

·         Review the multidisciplinary NCCN and ASCO guidelines for the identification and management of irAE

·         Apply guideline driven management irAE management to patient care

·         Understand and apply patient education principles in daily practice

·         Outline the mechanism of active of cytokine release syndrome (CRS) and CAR-T cell related encephalopathy syndrome (CRES) from CAR-T therapy

·         Recommend strategies for CRS and CRES management from CAR-T therapy

 

  • List Price: Free